Chancery Keeps Alive Suit Over Repriced Anixa Stock Options
Class claims that Anixa Biosciences Inc. directors down-priced stock options held by insiders in 2017 while delaying a new patent award announcement that bumped up option values survived a Chancery Court...To view the full article, register now.
Already a subscriber? Click here to view full article